PT - JOURNAL ARTICLE AU - van Loon, Welmoed AU - Rössig, Heike AU - Burock, Susen AU - Hofmann, Jörg AU - Bernhardt, Julian AU - Linzbach, Elizabeth AU - Pettenkofer, Domenika AU - Schönfeld, Christian AU - Gertler, Maximilian AU - Seybold, Joachim AU - Kurth, Tobias AU - Mockenhaupt, Frank P. TI - Emergence of the SARS-CoV-2 B.1.1.7 lineage and its characteristics at an outpatient testing site in Berlin, Germany, January-March 2021 AID - 10.1101/2021.04.15.21255389 DP - 2021 Jan 01 TA - medRxiv PG - 2021.04.15.21255389 4099 - http://medrxiv.org/content/early/2021/04/20/2021.04.15.21255389.short 4100 - http://medrxiv.org/content/early/2021/04/20/2021.04.15.21255389.full AB - Within five weeks in early 2021, B.1.1.7 became the dominant SARS-CoV-2 lineage at an outpatient testing site in Berlin. Characteristics including Ct-values of 193 and 125 recently ill outpatients with B.1.1.7 and wildtype virus, respectively, were similar, except for more commonly reported sore throat and travel, and less frequently stated loss of smell and taste in the former.Competing Interest StatementTK reports outside the topic of this paper to have received research grants from the German Federal Joint Committee and the German Ministry of Health. He further reports having received honoraria from Elie Lilly & Company, Total S.E., and Teva.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained from the Charit&eacute - Universit&aumltsmedizin Berlin institutional review board (EA4/083/20).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data presented in this study are available on reasonable request from the corresponding author.